John Clark (Interim CEO)
John Clark joined PharmAust with over 20 years of pharmaceutical industry experience in phase I – IV clinical trials across numerous therapeutic areas and multiple geographical regions. Most recently, John served as Senior Project Manager at a Global CRO, leading the Clinical Operations team and providing cross-functional oversight on a national CNS trial. Before that, John held various clinical operations leadership roles responsible for implementing clinical programs. John has a proven project management and stakeholder engagement record, with a thorough knowledge of ICH-GCP and regulatory requirements. John earned his B.Sc. in Biomedical Sciences from the University of the West of England.
Dr Carol Worth (CMC Operations Manager)
Dr Carol Worth brings over 30 years of industry experience and a passion for focusing on quality control and quality assurance. She recently served as Quality Manager at Epichem Pty Ltd as chief Technical Officer at Suda Pharmaceuticals and Solbec Pharmaceuticals. Carol has also led product development programs at Thermalife International Pty Ltd/ Pharmasolv Laboratories Pty Ltd.
Dr Michael Thurn
Michael has over 25 years experience in technical, regulatory, commercial and management roles in research organisations and industry, including early stage, fast growing, private and publicly listed biotechnology companies.
In the Biotechnology industry, Michael has held leadership roles at MARP Therapeutics, Botanix Pharmaceuticals (ASX:BOT), Mimetica, Spinifex Pharmaceuticals, Cytopia, Xenome and Novogen. During this time, he has guided a number of New Chemical Entities through discovery, preclinical and clinical development.
Michael has led a variety of US IND applications across a range of therapeutic areas and evaluated drugs and vaccines for registration during his engagement at the TGA. Michael currently sits on the Australian Boards of MARP Therapeutics, Impel Neuorpharma, Erasca and Inmagene.